부산대학교 도서관

Objective: This study aimed to investigate the correlation of sarcopenia with chemotherapy-ralated complications and oncological outcomes in endometrial cancer patient Methods: We collect the data from January, 2015 to August, 2021 by electronic medical records(EMR) and reviewed the pateints who underwent chemotherapy during those periods retrospectively. We assessed patients who had abdominopelvic computerized tomography(APCT) as part of follow up. We measured L3 vertebra skeletal muscle index(L3SMI) using Slice-O-Matic program(Tomovision) and sarcopenia was defined as L3SMI < 41cm2/m2. Results: Total 117 patients were underwent chemotherapy in our hospital and 97 patients were included our study finally. There are 28 patients in sarcopenia group, 69 patients in non-sarcopenia group. In the sarcopenia group, body mass index(BMI) before chemotherapy is lower than non-sarcopenia group (26.85±4.52 vs. 22.55±2.38; P < 0.0001). The prevalence of neutropenic fever in sarcopenia group was higher than non-sarcopenia group (42.9% vs. 18.8%, P = 0.0148). Whereas recurrence rate and prevalence of anemia after 1st chemotherapy were not associated with sarcopenia. Conclusion: In endometrial cancer, the patients with sarcopenia who underwent chemotherapy have increased chemotherapy- related complication as neutropenic fever. Neutropenic fever is mortal in patients who should be treated for malignancy by chemotherapy. Based on this result, it is necessary to use the Granulocyte-Colony Stimulating Factor(G-CSF) and pegfilgrastim prophylactically after chemotherapy for endometrial cancer patients with sarcopenia to prevent neutropenic fever. Additionally we should counsel about diet and exercise to prevent sarcopenia.